Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,740 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Renal Assessment Clear all
Completed Not applicable Interventional Results available

The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis

NCT00490841
View directory record Official record
Conditions
Renal Artery Obstruction, Hypertension, Renal
Interventions
Herculink Elite Renal Stent System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 7, 2026, 4:48 AM EDT
Completed No phase listed Observational

RBC Irradiation, Anemia and Gut Injury

NCT02741648
View directory record Official record
Conditions
Anemia, Necrotizing Enterocolitis
Interventions
Near Infrared Spectroscopy, Non-invasive Image-based Anemia Assessment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
1 Day to 5 Days
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 7, 2026, 4:48 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

NCT07146906
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
zigakibart
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Denver, Colorado • Acworth, Georgia • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 7, 2026, 4:48 AM EDT
Withdrawn Not applicable Interventional

Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)

NCT06603155
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Time restricted eating (TRE)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 7, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease

NCT04881448
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
collection of serum/capillary creatinine values
Diagnostic Test
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Huntsville, Alabama • Victorville, California • Bloomfield, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 7, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Belatacept in Reducing DSA

NCT02078193
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Belatacept
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 7, 2026, 4:48 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

NCT03326076
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
Diagnostic Test · Other
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
72
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 7, 2026, 4:48 AM EDT
Completed No phase listed Observational

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates

NCT02443389
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Minute to 2 Weeks
Enrollment
2,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Sep 7, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 7, 2026, 4:48 AM EDT
Recruiting Phase 3 Interventional

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 7, 2026, 4:48 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 7, 2026, 4:48 AM EDT
Not listed Not applicable Interventional

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

NCT05846113
View directory record Official record
Conditions
Kidney Diseases
Interventions
Renasight
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Anchorage, Alaska • Tucson, Arizona • Granada Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 7, 2026, 4:48 AM EDT
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 7, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 7, 2026, 4:48 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

NCT07106879
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
Interventions
Blood Work
Other
Lead sponsor
Clindove Research LLC
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 7, 2026, 4:48 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288
View directory record Official record
Conditions
Renal Allograft Recipients
Interventions
Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 7, 2026, 4:48 AM EDT
Terminated Phase 1Phase 2 Interventional

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

NCT04109482
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Interventions
MB-102, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Mustang Bio
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 7, 2026, 4:48 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effect of PARP Inhibitors on Glomerular Filtration Rate

NCT04367467
View directory record Official record
Conditions
Solid Tumor, Ovarian Cancer, Breast Cancer
Interventions
Kidney Function Test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 7, 2026, 4:48 AM EDT
Recruiting No phase listed Observational

Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities

NCT07748858
View directory record Official record
Conditions
Cardiovascular, Comorbidity, Diabetes, Inflammatory Joint Diseases, Chronic Kidney Diease, Chronic Obstructive Pulmonary Disease (COPD), Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 7, 2026, 4:48 AM EDT
Not listed No phase listed Observational

The QUALITY Vets Project: Muscle Quality and Kidney Disease

NCT03160326
View directory record Official record
Conditions
Chronic Kidney Disease, Sarcopenia
Interventions
Not listed
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 84 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 7, 2026, 4:48 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis

NCT06218290
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Oxylanthanum Carbonate
Drug
Lead sponsor
Unicycive Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Pine Bluff, Arkansas • Fort Myers, Florida • Gallup, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Sep 7, 2026, 4:48 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

NCT07763418
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 7, 2026, 4:48 AM EDT
Completed Not applicable Interventional

Living Kidney Donor Lost Wages Trial

NCT03268850
View directory record Official record
Conditions
Kidney Diseases
Interventions
Standard of Care, Wage Reimbursement A, Wage Reimbursement B
Other · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 7, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain

NCT00550654
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy, image-guided radiation therapy, tomotherapy
Other · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 7, 2026, 4:48 AM EDT